The treatment of gastroesophageal reflux disease with proton-pump inhibitors and its implications on managed care--pharmacoeconomics and its application to antisecretory drugs: a case study.
Morreale
A
A
Veterans Affairs San Diego Healthcare System, USA.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000191:economics* / Q000627:therapeutic use*; D002140:California; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D064747:Lansoprazole; D008329:Managed Care Programs; D009853:Omeprazole / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D019982:Organizational Case Studies; D017060:Patient Satisfaction; D054328:Proton Pump Inhibitors; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014493:United States Department of Veterans Affairs
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D009853:Omeprazole